CIK 0001637715 · <br>Emerging growth company
OnKure Therapeutics, Inc.
Sign in to watch- Ticker
- OKUR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472309515
- Phone
- (720) 307-2892
- Business address
- 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301
- Former names
- Reneo Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,157
- in 2 filings
Net −$1,157. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-27 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +130,000 | 130,000 | ||
| 2025-01-27 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2025-01-27 | Hartley Dylan Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-01-27 | Agresta Samuel Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-10-07 | Leonard Braden Michael Former 10% owner of RPHM | Other acquisition | +345,739 | 345,739 | ||
| 2024-10-07 | Leonard Braden Michael Former 10% owner of RPHM | Other acquisition | +102,076 | 102,076 | ||
| 2024-10-04 | Saccomano Nicholas A President and CEO | Grant or award | +4,556 | 4,556 | ||
| 2024-10-04 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +2,359 | 2,359 | ||
| 2024-10-04 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +1,485 | 1,485 | ||
| 2024-10-04 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +16,898 | 16,898 | ||
| 2024-10-04 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +8,449 | 8,449 | ||
| 2024-10-04 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +542,232 | 542,232 | ||
| 2024-10-04 | Phillips Andrew John Director | Grant or award · Stock Option (right to buy) | +15,300 | 15,300 | ||
| 2024-10-04 | Manke Isaac Director | Grant or award · Stock Option (right to buy) | +15,300 | 15,300 | ||
| 2024-10-04 | Leverone Jason A. Chief Financial Officer | Grant or award | +16,331 | 16,331 | ||
| 2024-10-04 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +5,781 | 5,781 | ||
| 2024-10-04 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +5,322 | 5,322 | ||
| 2024-10-04 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +130,611 | 130,611 | ||
| 2024-10-04 | Jansen Valerie Malyvanh Director | Grant or award · Stock Option (right to buy) | +15,300 | 15,300 | ||
| 2024-10-04 | Hartley Dylan Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +137,603 | 137,603 |
Page 5 of 8 · 154 trades